Cyclerion Therapeutics In... (CYCN)
2.75
0.07 (2.61%)
At close: Apr 17, 2025, 3:58 PM
2.61% (1D)
| Bid | 2.35 |
| Market Cap | 7.45M |
| Revenue (ttm) | 2M |
| Net Income (ttm) | -3.06M |
| EPS (ttm) | -1.21 |
| PE Ratio (ttm) | -2.27 |
| Forward PE | -0.14 |
| Analyst | n/a |
| Ask | 2.9 |
| Volume | 2,502 |
| Avg. Volume (20D) | 1,900,101 |
| Open | 2.64 |
| Previous Close | 2.68 |
| Day's Range | 2.64 - 2.75 |
| 52-Week Range | 1.27 - 9.47 |
| Beta | 1.96 |
About CYCN
Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serious central nervous system (CNS) diseases. Its lead product candidate is CY6463, a CNS-penetrant, soluble guanylate cyclase (sGC) stimulator that is in Phase IIa trials for the treatment of mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes, as well as Alzheimer's dis...
Industry Biotechnology
Sector Healthcare
IPO Date Mar 18, 2019
Employees 1
Stock Exchange NASDAQ
Ticker Symbol CYCN
Website https://www.cyclerion.com
